David B. Krizman, based in Gaithersburg, MD, is a notable inventor with an impressive portfolio of 47 patents. His innovative work primarily focuses on enhancing cancer diagnostics through advanced methodologies in mass spectrometry. With a keen eye on transforming biological sample analysis, Krizman has contributed significantly to the medical field.

Latest Patents

Krizman’s most recent patents include a multiplex MRM assay for evaluating cancer, which stands out for its capability to quantify critical proteins such as the estrogen receptor (ER), progesterone receptor (PR), and Ki67 in biological samples. This assay utilizes Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry techniques, allowing for the precise measurement of peptides from fixed biological tissues. His work specifically addresses the challenges of analyzing formalin-fixed samples, providing reagents and protocols that improve the quantitation of these proteins, be they in modified or unmodified forms.

Another significant patent is the development of an SRM/MRM assay for the tyrosine-protein kinase receptor UFO (AXL). This innovative method utilizes specific peptides to quantify the AXL protein in fixed biological samples, thereby contributing to improved cancer diagnostics. The applications of these techniques specifically target proteins in a variety of chemically preserved samples, showcasing Krizman's impact on protein quantitation in research and clinical environments.

Career Highlights

Throughout his career, David B. Krizman has worked with reputable organizations such as Expression Pathology Incorporated and the United States Department of Health and Human Services. His role in these institutions has furthered the development of analytical techniques that enhance our understanding of cancer biology and protein interactions. Krizman’s work continues to resonate within the medical community, contributing to advancements in diagnostics and therapeutic strategies.

Collaborations

Krizman has collaborated with esteemed colleagues, including Todd Hembrough and Sheeno Thyparambil, pooling their expertise to drive forward innovative research. These collaborations have fostered a creative atmosphere that embraces the contours of cutting-edge science and technology, fueling breakthroughs in healthcare.

Conclusion

David B. Krizman stands out as a pioneering inventor in the field of cancer research, holding 47 patents that underscore his significant contributions to the scientific community. His dedication to advancing diagnostic techniques through innovative methodologies highlights not just his skill as an inventor but also his commitment to improving patient outcomes in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.